By Daniella Parra
Glucotrack, Inc. (Nasdaq: GCTK) shared a study highlighting the long-term accuracy of its implantable blood glucose monitoring system as it moves closer to FDA clinical development and eventual commercialization, it said.
The results also align with earlier human trials, which showed similar accuracy and a high data capture rate without serious adverse events, it said.
“The publication of this peer-reviewed study in the Journal of Diabetes Research provides externally validated evidence of the long-term performance of our CBGM technology,” said Dr. Paul V. Goode, President and Chief Executive Officer of Glucotrack.
READ MORE
Final Agenda and Registration – 2nd Princeton CorpGov Forum: Endowments, Activism and Entertainment
Never Miss our Weekly Highlights HERE
